SBIR/STTR Research Award

FEASIBLITY ANALYSIS OF A CLINICAL ELECTROPORATION SYSTEM

Award identifier e55e63dc2d05619b8875c08dcbfaad7c4868f01e1e3ff8f44d6a1a5ba7c01cc7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$931,149

Program and phase

SBIR · Phase II

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ICHOR MEDICAL SYSTEMS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Q2Z1EV1XZWX9
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by Applicant):The primary goal of the project is the development of automated equipment suitable for the clinical application of Electroporation Therapy (EPT). This system will provide the foundation for clinical implementation of Ichor's proprietary therapy, which has shown promise for treatment of solid tumors in the pancreas, head & neck, liver, and brain. Preclinical studies performed by Ichor confirmed data reported in the literature characterize the cytotoxic effects of EPT. However, these studies also suggest that, unlike traditional EPT approaches, unique features of this therapy make it highly selective for malignant cells. Thus, the technology potentially offers a method of treatment for locally advanced tumors with margins that extend into surrounding tissues. Feasibility of the proposed EPT system will be established by designing, constructing, and testing a microprocessor-based switching apparatus. This system will directly control delivery of electroporation pulses to an electrode array implanted in the patient. Research will focus on the components, architecture, and control system best suited for safe application of the unique electrical signals characteristic of electroporation. After feasibility has been confirmed, integration of the switching apparatus with pulse generation and control means will provide an EPT system appropriate for multi-center clinical studies and eventual commercial use. PROPOSED COMMERCIAL APPLICATION: Electroporation Therapy with bleomycin (EPT-B) has potential as a locoregional treatment for both primary and secondary tumors. In both preclinical and early phase clinical studies, EPT-B has shown significant anti-tumor effect in a variety of tumor types. It appears that EPT-B could be clinically appropriate for several cancers including head & neck, pancreatic, liver, and brain. The proposed research will focus on the development of an Electroporation Therapy system appropriate for commercial clinical use.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

30 SBIR/STTR records share this UEI (1995–2011). Reported award amounts total $13,021,905. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.